NOV
Novo Nordisk A/S Class B · BSESOF:NOV
35.73 EUR1.05 +3.01%
Novo Nordisk A/S Class B (BSESOF:NOV) last traded at 35.73 EUR, up 3.01% on the day. Over the past year the stock is down 18.81%. Its 52-week range is 30.34 to 54.36. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open35.73
Day range35.73 – 35.73
52-week range30.34 – 54.36
Volume0
Average volume (10 days)7
Market cap (USD)175.64 B
P/E10.22
EPS (TTM) (USD)3.99
Dividend yield4.40%
Beta (1 year)1.88
Revenue (TTM) (USD)50.21 B
Employees68.79 K
Performance
+2.53%1 week
+6.83%1 month
−12.70%3 months
−0.21%6 months
−20.57%Year to date
−18.81%1 year
Technical rating
Buy
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Analysts’ target
40.98 EUR
The average 1-year price target, +14.71% from the last price. See the forecast
Latest headlines
- Weekly Recap: Wegovy scripts 265k+ and injunction denied in Eli Lilly ad suitTradingView · 02 Nov 2026
- Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
- Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
- Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
- LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.